Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13378442 | 0.85 | PREP (0.49) | PREPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13378487 | 0.85 | PREP (0.49) | PREPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2886001 | 0.85 | PREP (0.49) | PREPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19251183 | 0.84 | HTR2C (0.52) | CTRB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18296924 | 0.81 | PREP (0.53) | PREPACE2CTRB1NPC1RAB9A | |
| SCHEMBL3049973 | 0.79 | PREP (0.58) | PREPACE2KDM4ELMNAHSD17B10 | |
| SCHEMBL9873062 | 0.79 | PREP (0.83) | PREPACE2HSD17B10CTRB1NPC1 | |
| SCHEMBL10169570 | 0.78 | PREP (0.53) | PREPACE2 | |
| SCHEMBL9133051 | 0.78 | PREP (0.53) | PREPACE2HSD17B10CTRB1 | |
| SCHEMBL13769204 | 0.78 | PREP (0.57) | PREPKDM1ARCOR1ACE2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083900-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4244223-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | Biogen MA Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| WO-2022104079-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022104079-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083900-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BTK, SYK, LYN | PREP 2549/4885KDM1A 1323/4885RCOR1 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.